Glomerular Disease Clinical Case Review

Welcome to the Glomerular Disease Clinical Case Review, a series of case presentations by clinicians in the field of glomerular disease.

In this video, Craig Gordon, MD, nephrologist at Tufts Medical Center and associate professor of medicine at Tufts University School of Medicine, introduces a case of lupus nephritis:

Editor’s note: The following is an automatically generated transcript of the above video.

"I want to introduce myself. My name is Dr. Craig Gordon. I'm an associate professor of medicine at Tufts University School of Medicine and I work in the Tufts Medical Center Center for Glomerular Diseases. And today, we're going to be discussing the case of a young woman with lupus nephritis and to consider questions that all of us are grappling with since the fairly recent publications of randomized control trials of belimumab (Benlysta, GlaxoSmithKline), as well as voclosporin (Lupkynis, Aurinia), as well as the recently published 2024 update to the KDIGO guidelines on lupus nephritis.

I think a lot of treating clinicians are trying to come to grips with which patients would benefit from the addition of either belimumab or voclosporin to standard induction therapy for lupus. And so, I'm going to use a case to help us start the process of thinking about this when faced with seeing a patient with lupus nephritis and to highlight your attention to some very helpful guidance that's been provided by the KDIGO guidelines on lupus nephritis published earlier this year."